Steven J Skates

Steven J Skates

UNVERIFIED PROFILE

Are you Steven J Skates?   Register this Author

Register author
Steven J Skates

Steven J Skates

Publications by authors named "Steven J Skates"

Are you Steven J Skates?   Register this Author

54Publications

1514Reads

31Profile Views

Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.

J Clin Oncol 2017 May 27;35(13):1411-1420. Epub 2017 Feb 27.

Adam N. Rosenthal, Lindsay S.M. Fraser, Susan Philpott, Ranjit Manchanda, Matthew Burnell, Philip Badman, Richard Hadwin, Ivana Rizzuto, Andy Ryan, Robert Liston, Jeremy Ford, Richard Gunu, Usha Menon, and Ian J. Jacobs, University College London Elizabeth Garrett Anderson Institute for Women's Health; Elizabeth Benjamin, University College London; Naveena Singh, Barts Health National Health Service Trust; Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London; Anne Dawnay, University College London Hospital; James Mackay, The University College London Cancer Institute, London; D. Gareth Evans, University of Manchester, St Mary's Hospital Manchester, Manchester; Diana M. Eccles, Southampton General Hospital, Southampton, United Kingdom; Steven J. Skates, Massachusetts General Hospital and Harvard Medical School, Boston, MA; and Ian J. Jacobs, University of New South Wales Australia, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.69.9330
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.69.9330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455461PMC
May 2017

EPIC Early Detection of Ovarian Cancer.

Authors:
Steven J Skates

Clin Cancer Res 2016 Sep 14;22(18):4542-4. Epub 2016 Jul 14.

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026579PMC
September 2016

Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.

Int J Gynecol Cancer 2016 07;26(6):1070-7

*Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX; †Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; ‡Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX; and §Department of Biostatistics, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000737DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915986PMC
July 2016

Ovarian cancer screening: UKCTOCS trial - Authors' reply.

Lancet 2016 Jun;387(10038):2603-2604

Department of Women's Cancer, Institute for Women's Health, University College London, London W1T 7DN, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)30849-2DOI Listing
June 2016

Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Dis Markers 2014 23;2014:413946. Epub 2014 Nov 23.

School of Medicine and Pharmacology, University of Western Australia, M503, 23 Stirling Highway, Crawley, Perth, WA 6009, Australia ; National Centre for Asbestos Related Diseases, University of Western Australia, Nedlands, WA 6009, Australia ; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/413946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258360PMC
July 2015

Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.

J Clin Oncol 2015 Jun 11;33(18):2062-71. Epub 2015 May 11.

Usha Menon, Andy Ryan, Jatinderpal Kalsi, Aleksandra Gentry-Maharaj, Mariam Habib, Sophia Apostolidou, Matthew Burnell, Susan Davies, Richard Gunu, Martin Widschwendter, Elizabeth Benjamin, Mahesh Parmar, and Ian Jacobs, University College London; Anne Dawnay and Tim Mould, University College London Hospital; Naveena Singh, Barts and the London School of Medicine and Dentistry; David Oram and Karina Reynolds, St Bartholomew's Hospital; Alistair McGuire, London School of Economics; Stuart Campbell, Create Health Clinic; Aarti Sharma, University Hospital of Wales; Nazar N. Amso, Cardiff University, Cardiff; Keith Godfrey, Queen Elizabeth Hospital, Gateshead; Alberto Lopes, Royal Cornwall Hospital, Truro; Jonathan Herod, Liverpool Women's Hospital, Liverpool; Karin Williamson, Nottingham City Hospital, Nottingham; Mourad W. Seif, St Mary's Hospital, Manchester; Howard Jenkins and Ian Scott, Royal Derby Hospital, Derby; Robert Woolas, Queen Alexandra Hospital, Portsmouth; John B. Murdoch, St Michael's Hospital, Bristol; Stephen Dobbs, Belfast City Hospital, Belfast; Simon Leeson, Llandudno Hospital, Ysbyty Gwynedd; Derek Cruickshank, James Cook University Hospital, Middlesbrough; Lesley Fallowfield, University of Sussex, Falmer, United Kingdom; Steven J. Skates, Massachusetts General Hospital and Harvard Medical School, Boston, MA; and Ian Jacobs, UNSW Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.4945
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.4945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463475PMC
June 2015

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

J Natl Cancer Inst 2015 Apr 16;107(4). Epub 2015 Feb 16.

: Division of Cancer Control and Population Sciences (SDS, DMC, LEM, VPDR, MJK), Division of Cancer Prevention (SuS, BSK), and Division of Cancer Treatment and Diagnosis (LMM), National Cancer Institute, Bethesda, MD; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA, NU); Department of Medicine, University of North Carolina, Chapel Hill, NC (JAB, DFR); Department of Radiation Oncology, Johns Hopkins Medicine, Baltimore, MD (CDB); Center for Prostate Disease Research, Department of Defense, Rockville, MD (JC); Mount Sinai Hospital, Toronto, Ontario, Canada (EPD); Center for Health Research, Kaiser Permanente, Northwest, Portland, OR (KABG); Division of Biostatistics and Epidemiology, University of Massachusetts, Amherst, MA (SEH); Division of Research, Kaiser Permanente, Oakland, CA (LHK); Group Health Research Institute, Seattle, WA (EBL); American Society of Clinical Oncology, Alexandria, VA (RLS); Genomic Health, Inc., Redwood City, CA (StS); Biostatistics Center, Massachusetts General Hospital, Boston, MA (SJS); Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA (MJK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342676PMC
April 2015

Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer.

Gynecol Oncol 2014 Dec 23;135(3):547-51. Epub 2014 Oct 23.

Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.10.017DOI Listing
December 2014

Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.

BJOG 2014 Dec;121 Suppl 7:35-9

Gynaecology Cancer Research Unit, St Bartholomew's Hospital, The Royal Hospitals NHS Trust, London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.13211DOI Listing
December 2014

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Thorax 2014 Oct 18;69(10):895-902. Epub 2014 Jul 18.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia The Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://thorax.bmj.com/content/early/2014/07/18/thoraxjnl-201
Web Search
http://thorax.bmj.com/cgi/doi/10.1136/thoraxjnl-2014-205205
Publisher Site
http://dx.doi.org/10.1136/thoraxjnl-2014-205205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174124PMC
October 2014

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

J Clin Oncol 2014 Oct 8;32(29):3275-83. Epub 2014 Sep 8.

Mark E. Sherman, Phuong L. Mai, Lori Minasian, and Mark H. Greene, National Cancer Institute, Rockville; Olga B. Ioffe, University of Maryland Medical Center; Brigitte M. Ronnett, Johns Hopkins Medical Institutions, Baltimore; Chad A. Hamilton, Walter Reed National Military Medical Center, Bethesda, MD; Marion Piedmonte, Roswell Park Cancer Institute, Buffalo; Stephanie V. Blank, New York University School of Medicine; Noah D. Kauff, Memorial Sloan Kettering Cancer Center; New York, NY; Linda Van Le, University of North Carolina at Chapel Hill, Chapel Hill, NC; Iouri Ivanov, Columbus Cancer Council, Columbus, OH; Maria C. Bell, Sanford University of South Dakota Medical Center, Sioux Falls, SD; Paul DiSilvestro, Women and Infants Hospital, Providence, RI; Krishnansu S. Tewari, University of California Medical Center Irvine, Orange, CA; Katie Wakeley, Tufts University; Steven J. Skates, Massachusetts General Hospital, Boston, MA; S. Diane Yamada, University of Chicago, Chicago; Gustavo Rodriguez, North Shore University Health System, Evanston, IL; David S. Alberts, University of Arizona Cancer Center, Tucson, AZ; Joan L. Walker, University of Oklahoma, Oklahoma City, OK; and Karen Lu, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178524PMC
October 2014

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Dis Markers 2013 6;35(2):119-27. Epub 2013 Aug 6.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/dm/2013/874212/
Publisher Site
http://dx.doi.org/10.1155/2013/874212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774973PMC
June 2014

A statistical challenge: developing tests for biomarker utility specific to the intended use.

Authors:
Steven J Skates

J Natl Cancer Inst 2014 Apr 28;106(4):dju076. Epub 2014 Mar 28.

Affiliation of author: Biostatistics Center, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982897PMC
April 2014

Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.

Authors:
Steven J Skates

Int J Gynecol Cancer 2012 May;22 Suppl 1:S24-6

Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0b013e318256488aDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572791PMC
May 2012

Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Am J Obstet Gynecol 2012 Apr 30;206(4):351.e1-8. Epub 2011 Dec 30.

Center for Biomarkers and Emerging Technologies, Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2011.12.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985608PMC
April 2012

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Lung Cancer 2011 Oct 12;74(1):55-60. Epub 2011 Mar 12.

National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, 4th Floor, G Block, Verdun St, Nedlands, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.02.007DOI Listing
October 2011

Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.

Obstet Gynecol 2011 Aug;118(2 Pt 1):280-8

Department of Obstetrics and Gynecology and the Center for Biomarkers and Emerging Technologies, Program in Women's Oncology, Women and Infants' Hospital, Brown University, Providence, Rhode Island 02925, USA.

View Article

Download full-text PDF

Source
http://obgyn.med.umich.edu/sites/obgyn.med.umich.edu/files/E
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/AOG.0b013e318224fce2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594110PMC
August 2011

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Am J Obstet Gynecol 2010 Sep 14;203(3):228.e1-6. Epub 2010 May 14.

Program in Women's Oncology, Department of Obstetrics and Gynecology, Women & Infants Hospital of Rhode Island, Warren Alpert Medical School, Brown University, Providence, RI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2010.03.043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594101PMC
September 2010

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Cancer Epidemiol Biomarkers Prev 2010 Sep 22;19(9):2238-46. Epub 2010 Jul 22.

National Research Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, 2School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-10-0346DOI Listing
September 2010

Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.

Clin Chem 2010 Feb 10;56(2):237-43. Epub 2009 Dec 10.

National Cancer Institute-Food and Drug Administration Interagency Oncology Task Force on Molecular Diagnostics, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2009.136416DOI Listing
February 2010

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

J Thorac Oncol 2008 Aug;3(8):851-7

National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318180477bDOI Listing
August 2008

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.

Chest 2007 Oct 23;132(4):1239-46. Epub 2007 Jul 23.

National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://journal.publications.chestnet.org/data/Journals/CHEST
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S001236921536719
Publisher Site
http://dx.doi.org/10.1378/chest.07-0013DOI Listing
October 2007

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Thorax 2007 Jul 13;62(7):569-76. Epub 2007 Mar 13.

Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands 6009, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/thx.2006.068114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117248PMC
July 2007

Pooling of case specimens to create standard serum sets for screening cancer biomarkers.

Cancer Epidemiol Biomarkers Prev 2007 Feb;16(2):334-41

Biostatistics Center, Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-06-0681DOI Listing
February 2007

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

J Clin Oncol 2005 Nov;23(31):7919-26

Department of Gynecological Oncology, Institute of Women's Health, University College London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.01.6642DOI Listing
November 2005

Blood and urine markers for ovarian cancer: a comprehensive review.

Dis Markers 2004 ;20(2):53-70

Ob-Gyn Center Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839278PMC
http://dx.doi.org/10.1155/2004/241982DOI Listing
February 2005

Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.

Clin Cancer Res 2004 May;10(10):3474-8

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School, Dallas, Texas 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0365DOI Listing
May 2004

Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.

Clin Cancer Res 2003 Oct;9(13):4782-91

Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
October 2003

Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.

Clin Cancer Res 2003 Aug;9(8):2904-11

Department of Obstetrics & Gynecology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Harvard Cancer Center, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
August 2003

Progress in the management of gynecologic cancer: consensus summary statement.

J Clin Oncol 2003 May;21(10 Suppl):129s-132s

Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.04.003DOI Listing
May 2003

Screening for ovarian cancer-risk, education, worry: path to appropriate use?

Authors:
Steven J Skates

Gynecol Oncol 2002 Apr;85(1):1-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2002.6641DOI Listing
April 2002

Osteopontin as a potential diagnostic biomarker for ovarian cancer.

JAMA 2002 Apr;287(13):1671-9

Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.287.13.1671DOI Listing
April 2002